Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofol + remifentanil versus etomidate + remifentanil for painless gastroscopy in elderly patients
ChiCTR2400087849Phase 4Not yet recruiting
- Sponsor
- Yibin Second People's Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ciprofol, etomidate and remifentanil (2 arms), sponsored by Yibin Second People's Hospital. Primary endpoint: Incidence of respiratory and circulatory adverse reactions. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
ciprofoletomidateremifentanil
Beyond the preview
Go deeper on ChiCTR2400087849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087849.